Bionano Genomics, Inc. (BNGO) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presented mixed signals: a decline in software revenue and geographic narrowing suggest challenges, while improved margins and cost reductions are positive. The Q&A revealed management's reluctance to provide specific guidance, raising uncertainties. However, the expected revenue growth and potential catalysts like the CPT code price increase offer some optimism. Overall, the sentiment is neutral due to balanced positive and negative factors, and without market cap data, a more precise prediction is challenging.
Key Financial Performance
Q4 2025 Revenue $8 million, down 3% from $8.2 million in Q4 2024. The decline was due to supply constraints caused by delays from the manufacturing partner for silicon wafers, despite higher consumable demand.
Full Year 2025 Revenue $28.5 million, down 7% from $30.8 million in 2024. Adjusted for $1.7 million in discontinued clinical services in 2024, core revenue was down 2%.
Flowcells Sold in Q4 2025 7,554 units, down 6% year-over-year. The decline was attributed to supply constraints caused by manufacturing delays.
Flowcells Sold in Full Year 2025 30,171 units, down 0.4% year-over-year. Stability in customer base was noted despite the strategic shift.
OGM Systems Installed in Q4 2025 9 systems, contributing to a total of 32 installations for the full year 2025, exceeding the original guidance of 15-20 installations.
Non-GAAP Gross Margin for Q4 2025 43%, up from 42% in Q4 2024. The increase reflects efficiencies driven by the new strategy.
Non-GAAP Gross Margin for Full Year 2025 47%, up from 35% in 2024, an improvement of 1,200 basis points year-over-year, despite lower revenue.
Non-GAAP Operating Expense for Q4 2025 $9.7 million, down 9% year-over-year.
Non-GAAP Operating Expense for Full Year 2025 $36.6 million, down 47% from $68.9 million in 2024. This reflects a $100 million reduction in annualized non-GAAP operating expenses and a headcount reduction of over 300 people since Q2 2023.
Cash, Cash Equivalents, and Securities at Year-End 2025 $29.6 million, including $10.3 million subject to certain restrictions. The cash run rate is expected to extend into 2027.
Consumables and Software Revenue for Q4 2025 $4.8 million, down 1% year-over-year. Consumables grew 8%, but software revenue declined 22% due to orders pulled forward into prior quarters.
Consumables and Software Revenue for Full Year 2025 $20.4 million, up 7% from $19 million in 2024. This segment's share of total revenue increased from 62% in 2024 to 71% in 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Optical Genome Mapping (OGM) and VIA software: Focus on transforming pathology workflows to digital, AI-driven processes. Released VIA 7.2 software for expanded applications and improved ease of use.
Ionic system: Automates isolation of nucleic acids, enhancing ease of use for customers.
Geographic focus: Narrowed to the US, Canada, Western Europe, and Israel, with commercial partners supporting other regions.
Routine use customers: Targeting high-volume users with validated OGM protocols, accounting for 83% of consumables revenue.
Revenue and profitability: 2025 revenue was $28.5M, down 7% YoY. Non-GAAP gross margin improved to 47% from 35% in 2024. Operating expenses reduced by 47% YoY.
Consumables and software: Consumables and software revenue grew 7% YoY to $20.4M, representing 71% of total revenue.
Cost structure: Reduced annualized non-GAAP operating expenses by $100M since Q2 2023, with headcount reduced by over 300.
Strategic shift: Shifted focus from aggressive expansion to profitable growth from high-volume users and selective customer acquisition.
Reimbursement and guidelines: Secured two Category 1 CPT codes for OGM applications, with significant price increases for reimbursement.
Publications and adoption: Record 450 publications in 2025, supporting reimbursement and adoption. OGM consortia formed globally to promote usage.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Revenue for the fourth quarter of 2025 was $8 million, down 3% from $8.2 million in Q4 2024. Full-year 2025 revenue was $28.5 million, down 7% from $30.8 million in 2024.
Supply Chain Disruption: Late in Q4 2025, the manufacturing partner for silicon wafers experienced delays, leading to constrained supply against higher consumable demand.
Customer Base Stability: 2025 was a transitional year with uncertainty about the stability of the customer base during the strategic shift away from aggressive expansion to focusing on high-volume users.
Software Revenue Decline: Software revenue declined by 22% in Q4 2025, offsetting growth in consumables.
Geographic Focus Narrowing: The company narrowed its geographic focus to the U.S., Canada, most of Western Europe, and Israel, potentially limiting market opportunities elsewhere.
Dependence on Routine Use Customers: Routine use customers, while driving 83% of consumables revenue, represent less than half of the total customer base, indicating a reliance on a smaller subset of customers.
Reimbursement and Guideline Challenges: Efforts to build support for reimbursement and inclusion in medical society guidelines are ongoing, indicating potential hurdles in achieving broader adoption.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: Bionano is initiating revenue guidance of $30 million to $33 million for the full year 2026, representing growth of 5% to 16% over 2025.
Q1 2026 Revenue Guidance: Revenue guidance for the first quarter of 2026 is set at $6.5 million to $6.7 million, representing flat to 3% growth over Q1 2025.
Consumables Revenue Growth: The company expects consumables revenue to grow as routine use customers expand their menus to include new applications and validate their protocols.
Profitability and Scalability: Bionano anticipates margin expansion in line with revenue growth as volumes increase and product mix shifts towards consumables. This will support progress toward EBITDA breakeven.
Reimbursement and Guidelines: Reimbursement improved significantly with the establishment of a second Category 1 CPT code for OGM in constitutional genetic disorders, priced at $1,263.53. The 2026 clinical lab fee schedule also reflects a 47% increase in the payment determination for the Category 1 CPT code for OGM in hematologic malignancies, now priced at $1,853.22.
Operational Scale and Adoption: Bionano expects OGM to move from early adoption to operation at scale, with academic networks, medical centers, and national reference laboratories building operational use cases for it.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you give us any color on what your expectations regarding how many new OGM systems could be installed during 2026?
A:The company expects a comparable number of new OGM systems to what was shipped last year but is not providing specific guidance. They emphasize flexibility and note that they significantly overperformed guidance last year.
Q:How should we expect the number of nanochannel Flowcells to be sold this year? Do you expect that to be relatively flat as well?
A:The company does not expect the number of nanochannel Flowcells to be flat. Revenue growth will be driven by new systems and consumables at existing customers. Consumables volume is expected to track with revenue growth, which has a wide range. Routine users grew in 2025 over 2024, but supply constraints at the end of the year limited additional growth.
Q:How many nanochannel or new OGM systems do you need to sell to achieve the guidance for 2026 of $30 million to $33 million, translating to approximately 5% to 16% top-line growth? Are there any catalysts expected in 2026 to achieve this growth?
A:The company did not provide a specific number of systems needed to achieve the guidance. Growth is expected to come from increasing productivity among routine users, converting customers to validated OGM protocols, and expanding revenues among validated users. A major catalyst is the 47% increase in the price determination for the hematologic malignancy CPT code 81195, effective January 1, 2026, which is expected to accelerate adoption and utilization.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers for the expected new OGM systems to be installed in 2026 and the number of systems needed to achieve the 2026 revenue guidance. They emphasized flexibility and focused on general growth drivers instead of offering precise details.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Accounting Controller
Campbell Gilmartin
Controller end
Director Webb
Flowcells OGM
Flowcells manufacturing
Full Conference
Full Financial
Full result
Gilmartin Group
Group afternoon
Officer highlight
Reconciliations measure
VP Accounting
Webb Campbell
Webb afternoon
achievement
afternoon Full
analog workflow
array Flowcells
automation AI
backlog consumables
base composition
basis point
cash run
chip consumables
composition customer
conference Webb
consolidation automation
constraint ease
consumables experience
consumables quarter
context space
copy press
core Flowcells
pathology
profile
BNGO Transcript
Bionano Genomics, Inc. (BNGO) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call reveals a mixed financial performance: a 15% revenue increase and improved gross margin are positive, but rising operating expenses and net loss are concerning. The lack of strategic updates and forward-looking caution adds uncertainty. Overall, the sentiment is neutral, reflecting balanced positives and negatives.
Bionano Genomics, Inc. (BNGO) Q4 2025 Earnings Call Transcript
Unknown3-23
The earnings call presented mixed signals: a decline in software revenue and geographic narrowing suggest challenges, while improved margins and cost reductions are positive. The Q&A revealed management's reluctance to provide specific guidance, raising uncertainties. However, the expected revenue growth and potential catalysts like the CPT code price increase offer some optimism. Overall, the sentiment is neutral due to balanced positive and negative factors, and without market cap data, a more precise prediction is challenging.
Bionano Genomics, Inc. (BNGO) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings report indicates positive financial performance with revenue growth and improved margins, but there are concerns regarding liquidity constraints and profitability challenges. The Q&A session highlighted uncertainties in achieving target utilization levels and market expansion timelines. Despite a new CPT code and increased system installations, the dependency on routine users and economic uncertainties pose risks. The recent stock offering and restricted cash further temper optimism. Given these mixed signals, the stock price is expected to remain relatively stable over the next two weeks.
Bionano Genomics, Inc. (BNGO) Q2 2025 Earnings Call Transcript
Unknown8-15
The earnings call presents a mixed picture. Financial performance shows a revenue decline but improved margins and cost reductions. Product development highlights growth in flowcell utilization and software adoption. However, market competition and system returns pose risks. The Q&A reveals opportunities for software expansion and strategic partnerships but also highlights uncertainties in system returns and reimbursement pricing. Overall, the sentiment is neutral, reflecting balanced positive and negative factors without a clear catalyst for significant stock price movement.
BNGO Slides
BNGO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
